Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 12/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.68 |
| ▸ | PGR | P06401 | 6/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | AR | P10275 | 2/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.68 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.68 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.61 |
| ▸ | CNR1 | P21554 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 3/20 | 0.60 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | MLNR | O43193 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4224907 | 1.00 | NR3C1 (0.68) | NR3C1CYP3A4PGRLMNAAR | |
| SCHEMBL11081794 | 0.93 | NR3C1 (0.68) | NR3C1CYP3A4PGRLMNAAR | |
| SCHEMBL4224909 | 0.92 | NR3C1 (0.67) | NR3C1CYP3A4PGRLMNAAR | |
| SCHEMBL4003695 | 0.92 | NR3C1 (0.67) | NR3C1CYP3A4PGRLMNAAR | |
| SCHEMBL11037864 | 0.91 | NR3C1 (0.72) | NR3C1CYP3A4PGRLMNAAR | |
| SCHEMBL4102916 | 0.91 | NR3C1 (0.72) | NR3C1CYP3A4PGRLMNAAR | |
| SCHEMBL11251406 | 0.91 | NR3C1 (0.72) | NR3C1CYP3A4PGRLMNAAR | |
| SCHEMBL4216341 | 0.91 | NR3C1 (0.66) | NR3C1CYP3A4PGRLMNAAR | |
| SCHEMBL11037205 | 0.90 | NR3C1 (0.83) | NR3C1CYP3A4PGRLMNAAR | |
| SCHEMBL4008052 | 0.89 | NR3C1 (0.78) | NR3C1CYP3A4PGRLMNAAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2067784-A2 | 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivates as anti-flammatory agents | Glaxo Group Limited (GB) | 2009-06-10 | — | — | EP | disclosed |
| US-7498321-B2 | 17β-carbothioate 17α-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents | GLAXO GROUP LIMITED (GB) | 2009-03-03 | — | — | US | disclosed |
| EP-1305330-B1 | 17.BETA.-CARBOTHIOATE 17.ALPHA.-ARYLCARBONYLOXYLOXY ANDROSTANE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | GLAXO GROUP LTD (GB) | 2008-12-03 | — | — | EP | disclosed |
| US-7405206-B2 | Anti-inflammatory androstane derivatives | GLAXO GROUP LIMITED (GB) | 2008-07-29 | — | — | US | disclosed |
| EP-1444248-B1 | NOVEL ANTI-INFLAMMATORY ANDROSTANE DERIVATIVES - 17-CARBOXY-LACTONE SUBSTITUTED STEROIDS WITH AN ARYL-CARBOXYLIC ESTER IN POSITION 17.ALPHA | GLAXO GROUP LTD (GB) | 2008-04-30 | — | — | EP | disclosed |
| EP-1757281-A2 | Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist | GLAXO GROUP LIMITED (GB) | 2007-02-28 | — | — | EP | disclosed |
| US-6878698-B2 | Anti-inflammatory androstane derivatives | GLAXO GROUP LIMITED (GB) | 2005-04-12 | — | — | US | disclosed |
| US-20050054622-A1 | Novel anti-inflammatory androstane derivatives | GLAXO GROUP LIMITED (GB) | 2005-03-10 | — | — | US | disclosed |
| US-20040028615-A1 | 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents | GLAXOSMITHKLINE INTELLECTUAL PROPERTY MANAGEMENT LIMITED (GB) | 2004-02-12 | — | — | US | disclosed |
| US-20030092690-A1 | Novel anti-inflammatory androstane derivatives | GLAXOSMITHKLINE INTELLECTUAL PROPERTY MANAGEMENT LIMITED (GB) | 2003-05-15 | — | — | US | disclosed |
| US-6537983-B1 | An ene or diene steroid inhaler for treating asthma, once-per-day dosing | SMITHKLINE BEECHAM CORPORATION | 2003-03-25 | — | — | US | disclosed |
| US-20030045512-A1 | NOVEL ANTI-INFLAMMATORY ANDROSTANE DERIVATIVES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY MANAGEMENT LIMITED (GB) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092690-A1 | Novel anti-inflammatory androstane derivatives | ADRB1, ADRB2, ADRB3 | NR3C1 7/4885CYP3A4 269/4885PGR 400/4885 |
| US-20040028615-A1 | 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents | HSD17B1, HSD17B7, HSD3B1 | NR3C1 9/4885CYP3A4 264/4885PGR 491/4885 |
| US-20050054622-A1 | Novel anti-inflammatory androstane derivatives | NR5A1, HSD3B2, HSD3B1 | NR3C1 10/4885CYP3A4 211/4885PGR 66/4885 |
| US-20030045512-A1 | NOVEL ANTI-INFLAMMATORY ANDROSTANE DERIVATIVES | ADRB1, NR3C2, NR3C1 | NR3C1 3/4885CYP3A4 209/4885PGR 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.